# **Special Issue**

# Microbiome-Based Medicinal Products: The Next Frontier in Medicine

## Message from the Guest Editor

The recent discovery of the importance of microbiomes in health has revolutionized the way we think about disease management and therapies. As a consequence, a number of microbiome-based medicinal products (MMPs) are now being developed to address a range of diseases. The objective of this Special Issue is to collect state-of-the-art articles that broadly cover the full range of microbiome-derived therapies. These may include original results or reviews discussing the development of any MMPs, such as fecal material transplants, bacterial consortia, single strain live biotherapeutic products, bacteriophages, postbiotics, and generally any molecules targeting human-associated microbiomes. Since many of these therapies rely on precise characterization of microbiome signatures, the collection will also include articles reporting on the development of diagnostic assays. Reflections on manufacturing challenges and the regulatory landscape surrounding the MMP development field are also welcome.

#### **Guest Editor**

Dr. Sandrine P. Claus

Ysopia Bioscience, 17 Place de la Bourse, 33076 Bordeaux, France

### Deadline for manuscript submissions

closed (30 June 2023)



# Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/129406

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/ microorganisms





# Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

### Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

### Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

